Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid-refractory acute graft-versus-host disease

British Journal of Haematology

Volumn 130, Issue 4, 2005, Pages 568-574

  Schmidt Hieber, Martin ^a   Fietz, Thomas ^a   Knauf, Wolfgang ^b   Uharek, Lutz ^a   Hopfenmüller, Werner ^a   Thiel, Eckhard ^a   Blau, Igor Wolfgang ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Bethanien Krankenhaus Frankfurt   (Germany)

Author keywords

Acute GVHD; Basiliximab; Interleukin 2 receptor; Stem cell transplantation

Indexed keywords

BASILIXIMAB; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DACLIZUMAB; FLUDARABINE; FOSCARNET SODIUM; GANCICLOVIR; INTERLEUKIN 2 RECEPTOR ALPHA; METHOTREXATE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; THYMOCYTE ANTIBODY; TREOSULFAN; HYBRID PROTEIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIBIOTIC THERAPY; ARTICLE; B CELL LEUKEMIA; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; BRONCHITIS; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CAUSE OF DEATH; CHIMERA; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DONOR; DRUG EFFECT; DRUG EFFICACY; DRUG TREATMENT FAILURE; EVALUATION; FEASIBILITY STUDY; FEMALE; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; MALE; MORBIDITY; MORTALITY; MULTIPLE MYELOMA; MYCOSIS; MYELOABLATIVE CONDITIONING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT DISEASE; REDUCED INTENSITY CONDITIONING; SEPSIS; TOXOPLASMOSIS; TREATMENT RESPONSE; VIRUS INFECTION; WHOLE BODY RADIATION; ACUTE DISEASE; ALLOTRANSPLANTATION; BLOOD DISEASE; DRUG ANTAGONISM; DRUG TOLERANCE; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; TREATMENT OUTCOME;

ACUTE DISEASE; ADULT; ANTIBODIES, MONOCLONAL; DRUG TOLERANCE; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, INTERLEUKIN-2; RECOMBINANT FUSION PROTEINS; STEROIDS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 24944433163     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2005.05631.x     Document Type: Article

References (44)

1. Antin J.H. Chen A.R. Couriel D.R. Ho V.T. Nash R.A. Weisdorf D. ( 2004) Novel approaches to the therapy of steroid-resistant acute graft-versus-host disease. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation, 10, 655 668.
2. Arai S. Vogelsang G.B. ( 2000) Management of graft-versus-host disease. Blood Reviews, 14, 190 204.
3. Basara N. Blau I.W. Willenbacher W. Kiehl M.G. Fauser A.A. ( 2000) New strategies in the treatment of graft-versus-host disease. Bone Marrow Transplantation, 25, 12 15.
4. Blaise D. Olive D. Michallet M. Marit G. Leblond V. Maraninchi D. ( 1995) Impairment of leukaemia-free survival by addition of interleukin-2-receptor antibody to standard graft-versus-host prophylaxis. Lancet, 345, 1144 1146.
5. Boeckh M. Nichols W.G. Papanicolaou G. Rubin R. Wingard J.R. Zaia J. ( 2003) Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation, 9, 543 558.
6. Bolanos-Meade J. Vogelsang G.B. ( 2005) Novel strategies for steroid-refractory acute graft-versus-host disease. Current Opinion in Haematology, 12, 40 44.
7. Chen H.R. Ji S.Q. Wang H.X. Yan H.M. Zhu L. Liu J. Xue M. Xun C.Q. ( 2003) Humanized anti-CD25 monoclonal antibody for prophylaxis of graft-vs-host disease (GVHD) in haploidentical bone marrow transplantation without ex vivo T-cell depletion. Experimental Haematology, 31, 1019 1025.
8. Couriel D. Caldera H. Champlin R. Komanduri K. ( 2004) Acute graft-versus-host disease: pathophysiology, clinical manifestations, and management. Cancer, 101, 1936 1946.
9. Deeg H.J. Blazar B.R. Bolwell B.J. Long G.D. Schuening F. Cunningham J. Rifkin R.M. Abhyankar S. Briggs A.D. Burt R. Lipani J. Roskos L.K. White J.M. Havrilla N. Schwab G. Heslop H.E. ( 2001) Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL. Blood, 98, 2052 2058.
10. Dieckmann D. Bruett C.H. Ploettner H. Lutz M.B. Schuler G. ( 2002) Human CD4(+)CD25(+) regulatory, contact-dependent T cells induce interleukin 10-producing, contact-independent type 1-like regulatory T cells. The Journal of Experimental Medicine, 196, 247 253.
11. Ding H. Ren H. Guo N. Huang X. Xu L. Zhang Y. Lu D. ( 2003) Risk factors of cytomegalovirus infection and antiviral efficacy in recipients of hematopoietic stem cell transplantation. Journal of Peking University Health Sciences, 35, 596 599.
12. Edinger M. Hoffmann P. Ermann J. Drago K. Fathman C.G. Strober S. Negrin R.S. ( 2003) CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nature Medicine, 9, 1144 1150.
13. Ferrara J.L. Deeg H.J. ( 1991) Graft-versus-host disease. The New England Journal of Medicine, 324, 667 674.
14. Fukuda T. Boeckh M. Carter R.A. Sandmaier B.M. Maris M.B. Maloney D.G. Martin P.J. Storb R.F. Marr K.A. ( 2003) Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood, 102, 827 833.
15. Gesbert F. Delespine-Carmagnat M. Bertoglio J. ( 1998) Recent advances in the understanding of interleukin-2 signal transduction. Journal of Clinical Immunology, 18, 307 320.
16. Goker H. Haznedaroglu I.C. Chao N.J. ( 2001) Acute graft-vs-host disease: pathobiology and management. Experimental Haematology, 29, 259 277.
17. Henry M.L. Rajab A. ( 2002) The use of basiliximab in solid organ transplantation. Expert Opinion on Pharmacotherapy, 3, 1657 1663.
18. Jacobsohn D.A. Vogelsang G.B. ( 2004) Anti-cytokine therapy for the treatment of graft-versus-host disease. Current Pharmaceutical Design, 10, 1195 1205.
19. Ji S.Q. Chen H.R. Wang H.X. Yan H.M. Liu J. Xue M. Zhu L. ( 2002) A clinical study of haploidentical and G-CSF primed bone marrow transplantation by using CD25 for aGVHD prophylaxis. Journal of Experimental Haematology/Chinese Association of Pathophysiology, 10, 447 451.
20. Kovarik J. Wolf P. Cisterne J.M. Mourad G. Lebranchu Y. Lang P. Bourbigot B. Cantarovich D. Girault D. Gerbeau C. Schmidt A.G. Soulillou J.P. ( 1997) Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts. Transplantation, 64, 1701 1705.
21. Lee S.J. Vogelsang G. Flowers M.E. ( 2003) Chronic graft-versus-host disease. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation, 9, 215 233.
22. Lee S.J. Zahrieh D. Agura E. MacMillan M.L. Maziarz R.T. McCarthy P.L. Jr. Ho V.T. Cutler C. Alyea E.P. Antin J.H. Soiffer R.J. ( 2004) Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood, 104, 1559 1564.
23. Marr K.A. Bowden R.A. ( 1999) Fungal infections in patients undergoing blood and marrow transplantation. Transplant Infectious Disease: An Official Journal of the Transplantation Society, 1, 237 246.
24. Martin P.J. Schoch G. Fisher L. Byers V. Anasetti C. Appelbaum F.R. Beatty P.G. Doney K. McDonald G.B. Sanders J.E. Sullivan K.M. Storb R. Thomas E.D. Witherspoon R.P. Lomen P. Hannigan J. Hansen J.A. ( 1990) A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood, 76, 1464 1472.
25. Martin P.J. Schoch G. Fisher L. Byers V. Appelbaum F.R. McDonald G.B. Storb R. Hansen J.A. ( 1991) A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. Blood, 77, 1821 1828.
26. Massenkeil G. Rackwitz S. Genvresse I. Rosen O. Dorken B. Arnold R. ( 2002) Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation. Bone Marrow Transplantation, 30, 899 903.
27. Mills G.B. Schmandt R. Gibson S. Leung B. Hill M. May C. Shi Y.F. Branch D.R. Radvanyi L. Truitt K.E. Imboden J. ( 1993) Transmembrane signaling by the interleukin-2 receptor: progress and conundrums. Seminars in Immunology, 5, 345 364.
28. Pasquini R. Moreira V.A. de Medeiros C.R. Bonfim C. ( 2000) Basiliximab (BaMab) - a selective interleukin-2 receptor (Il-2R) antagonist - as therapy for refractory acute graft versus host disease (aGVHD) following bone marrow transplantation (BMT). Blood, 11, 177a (abstract 762).
29. Przepiorka D. Weisdorf D. Martin P. Klingemann H.G. Beatty P. Hows J. Thomas E.D. ( 1995) 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplantation, 15, 825 828.
30. Przepiorka D. Ippoliti C. Khouri I. Woo M. Mehra R. Le Bherz D. Giralt S. Gajewski J. Fischer H. Fritsche H. Deisseroth A.B. Cleary K. Champlin R. Besien K. Andersson B. Maher R. Fitzsimmons W. ( 1996) Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation. Blood, 88, 4383 4389.
31. Przepiorka D. Kernan N.A. Ippoliti C. Papadopoulos E.B. Giralt S. Khouri I. Lu J.G. Gajewski J. Durett A. Cleary K. Champlin R. Andersson B.S. Light S. ( 2000) Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood, 95, 83 89.
32. Przepiorka D. Anderlini P. Saliba R. Cleary K. Mehra R. Khouri I. Huh Y.O. Giralt S. Braunschweig I. van Besien K. Champlin R. ( 2001) Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood, 98, 1695 1700.
33. Simon R. ( 1989) Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials, 10, 1 10.
34. Simpson D. ( 2001) New developments in the prophylaxis and treatment of graft versus host disease. Expert Opinion on Pharmacotherapy, 2, 1109 1117.
35. Subira M. Martino R. Rovira M. Vazquez L. Serrano D. De La Camara R. ( 2003) Clinical applicability of the new EORTC/MSG classification for invasive pulmonary aspergillosis in patients with hematological malignancies and autopsy-confirmed invasive aspergillosis. Annals of Hematology, 82, 80 82.
36. Tanimoto T.E. Yamaguchi T. Tanaka Y. Saito A. Tajima K. Karasuno T. Kasai M. Kishi K. Mori T. Maseki N. Morishima S. Miyakoshi S. Kasai M. Ohno Y. Kim S.W. Numata A. Kami M. Takaue Y. Mori S. Harada M. ( 2004) Comparative analysis of clinical outcomes after allogeneic bone marrow transplantation versus peripheral blood stem cell transplantation from a related donor in Japanese patients. British Journal of Heamatology, 125, 480 493.
37. Taylor P.A. Lees C.J. Blazar B.R. ( 2002) The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood, 99, 3493 3499.
38. Van Burik J.A. Weisdorf D.J. ( 1999) Infections in recipients of blood and marrow transplantation. Hematology/Oncology Clinics of North America, 13, 1065 1089.
39. Van Gelder T. Warle M. Ter Meulen R.G. ( 2004) Anti-interleukin-2 receptor antibodies in transplantation: what is the basis for choice? Drugs, 64, 1737 1741.
40. Via C.S. Finkelman F.D. ( 1993) Critical role of interleukin-2 in the development of acute graft-versus-host disease. International Immunology, 5, 565 572.
41. Vincenti F. Kirkman R. Light S. Bumgardner G. Pescovitz M. Halloran P. Neylan J. Wilkinson A. Ekberg H. Gaston R. Backman L. Burdick J. ( 1998) Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. The New England Journal of Medicine, 338, 161 165.
42. Webster A.C. Playford E.G. Higgins G. Chapman J.R. Craig J.C. ( 2004) Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation, 77, 166 176.
43. Weisdorf D. Haake R. Blazar B. Miller W. McGlave P. Ramsay N. Kersey J. Filipovich A. ( 1990) Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood, 75, 1024 1030.
44. Willenbacher W. Basara N. Blau I.W. Fauser A.A. Kiehl M.G. ( 2001) Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab. British Journal of Heamatology, 112, 820 823.